References
- HayatMJHowladerNReichmanMEEdwardsBKCancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramOncologist2007121203717227898
- HolickCNGiovannucciELRosnerBStampferMJMichaudDSProspective study of cigarette smoking and adult glioma: dosage, duration, and latencyNeuro Oncol20079332633417504930
- HuncharekMKupelnickBWheelerLDietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studiesJ Environ Pathol Toxicol Oncol200322212913714533876
- KaripidisKKBenkeGSimMROccupational exposure to ionizing and non-ionizing radiation and risk of non-Hodgkin lymphomaInt Arch Occup Environ Health200780866367017334774
- KaripidisKKBenkeGSimMRYostMGilesGOccupational exposure to low frequency magnetic fields and the risk of low grade and high grade gliomaCancer Causes Control200718330531317260179
- InskipPDTaroneREHatchEECellular-telephone use and brain tumorsN Engl J Med20013442798611150357
- VilchezRAButelJSEmergent human pathogen simian virus 40 and its role in cancerClin Microbiol Rev200417349550815258090
- ReussDvon DeimlingAHereditary tumor syndromes and gliomasRecent Results Cancer Res20091718310219322539
- KrexDKlinkBHartmannCLong-term survival with glioblastoma multiformeBrain2007130Pt 102596260617785346
- SmithJSJenkinsRBGenetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implicationsFront Biosci20005D213D23110702383
- LacroixMAbi-SaidDFourneyDRA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg200195219019811780887
- HessKRExtent of resection as a prognostic variable in the treatment of gliomasJ Neurooncol199942322723110433106
- MetcalfeSEGrantRBiopsy versus resection for malignant gliomaCochrane Database Syst Rev20013CD00203411687008
- BloomHJCombined modality therapy for intracranial tumorsCancer1975351111120162849
- SalazarOMRubinPFeldsteinMLPizzutielloRHigh dose radiation therapy in the treatment of malignant gliomas: final reportInt J Radiat Oncol Biol Phys197951017331740231023
- WalkerMDAlexanderEJrHuntWEEvaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trialJ Neurosurg1978493333343355604
- WalkerMDGreenSBByarDPRandomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgeryN Engl J Med198030323132313297001230
- WalkerMDStrikeTAShelineGEAn analysis of dose-effect relationship in the radiotherapy of malignant gliomasInt J Radiat Oncol Biol Phys197951017251731231022
- FineHADearKBLoefflerJSBlackPMCanellosGPMeta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer1993718258525978453582
- CairncrossJGMacdonaldDRSuccessful chemotherapy for recurrent malignant oligodendrogliomaAnn Neurol19882343603643382171
- StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
- WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol19991782572257810561324
- WHLThe vascular pattern of tumorsJohns Hopkins Hosp Bull192741156162
- FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
- FolkmanJAnti-angiogenesis: new concept for therapy of solid tumorsAnn Surg197217534094165077799
- FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
- SholleyMMFergusonGPSeibelHRMontourJLWilsonJDMechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cellsLab Invest19845166246346209468
- FolkmanJAngiogenesis in psoriasis: therapeutic implicationsJ Invest Dermatol197259140435039962
- MillerJWAdamisAPShimaDTVascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate modelAm J Pathol199414535745847521577
- MoultonKSAngiogenesis in atherosclerosis: gathering evidence beyond speculationCurr Opin Lipidol200617554855516960504
- FerraraNVEGF and the quest for tumour angiogenesis factorsNat Rev Cancer200221079580312360282
- BalukPHashizumeHMcDonaldDMCellular abnormalities of blood vessels as targets in cancerCurr Opin Genet Dev200515110211115661540
- HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
- FolkmanJAngiogenesis: an organizing principle for drug discovery?Nat Rev Drug Discov20076427328617396134
- FolkmanJIs angiogenesis an organizing principle in biology and medicine?J Pediatr Surg200742111117208533
- KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
- FangJShingYWiederschainDMatrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor modelProc Natl Acad Sci U S A20009783884388910760260
- MaxwellPHDachsGUGleadleJMHypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growthProc Natl Acad Sci U S A19979415810481099223322
- ShweikiDItinASofferDKeshetEVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature199235963988438451279431
- PlateKHBreierGWeichHARisauWVascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature199235963988458481279432
- AugustePGurselDBLemiereSInhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanismsCancer Res20016141717172611245488
- SalmaggiAEoliMFrigerioSIntracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant gliomaJ Neurooncol200362329730312777082
- SchmidtNOWestphalMHagelCLevels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesisInt J Cancer199984110189988225
- LiMRansohoffRMThe roles of chemokine CXCL12 in embryonic and brain tumor angiogenesisSemin Cancer Biol200919211111519038344
- HallbookFWilsonKThorndykeMOlinskiRPFormation and evolution of the chordate neurotrophin and Trk receptor genesBrain Behav Evol200668313314416912467
- HuangEJReichardtLFTrk receptors: roles in neuronal signal transductionAnnu Rev Biochem20037260964212676795
- NicoBMangieriDBenagianoVCrivellatoERibattiDNerve growth factor as an angiogenic factorMicrovasc Res200875213514117764704
- KraemerRHempsteadBLNeurotrophins: novel mediators of angiogenesisFront Biosci20038s1181118612957860
- HoodJDChereshDARole of integrins in cell invasion and migrationNat Rev Cancer2002229110012635172
- SunLHuiAMSuQNeuronal and glioma-derived stem cell factor induces angiogenesis within the brainCancer Cell20069428730016616334
- SengerDRGalliSJDvorakAMPerruzziCAHarveyVSDvorakHFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience198321945879839856823562
- FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun198916128518582735925
- ConnollyDTOlanderJVHeuvelmanDHuman vascular permeability factor. Isolation from U937 cellsJ Biol Chem19892643320017200242584205
- HouckKAFerraraNWinerJCachianesGLiBLeungDWThe vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNAMol Endocrinol1991512180618141791831
- LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
- de VriesCEscobedoJAUenoHHouckKFerraraNWilliamsLTThe fms-like tyrosine kinase, a receptor for vascular endothelial growth factorScience199225550479899911312256
- ShibuyaMYamaguchiSYamaneANucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms familyOncogene1990545195242158038
- OlssonAKDimbergAKreugerJClaesson-WelshLVEGF receptor signalling – in control of vascular functionNat Rev Mol Cell Biol20067535937116633338
- TermanBIDougher-VermazenMCarrionMEIdentification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochem Biophys Res Commun19921873157915861417831
- TakahashiMMatsuiAInaoMMochidaSFujiwaraKERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cellsHepatol Res200326323223612850696
- TakahashiTShibuyaMThe 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblastsOncogene19971417207920899160888
- JonesMKItaniRMWangHActivation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injuryAm J Physiol19992766 Pt 1G1345G135510362637
- GerberHPMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activationJ Biol Chem19982734630336303439804796
- GilleHKowalskiJLiBAnalysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutantsJ Biol Chem200127653222323011058584
- HellstromMPhngLKHofmannJJDll4 signalling through Notch1 regulates formation of tip cells during angiogenesisNature2007445712977678017259973
- RidgwayJZhangGWuYInhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesisNature200644471221083108717183323
- Noguera-TroiseIDalyCPapadopoulosNJBlockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesisNature200644471221032103717183313
- BoultonMECaiJGrantMBgamma-Secretase: a multifaceted regulator of angiogenesisJ Cell Mol Med200812378179518266961
- SelkoeDKopanRNotch and Presenilin: regulated intramembrane proteolysis links development and degenerationAnnu Rev Neurosci20032656559712730322
- BoultonMECaiJGrantMBZhangYGamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPEAdv Exp Med Biol200861331331918188959
- HiranoHLopesMBLawsERJrInsulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomasNeuro Oncol19991210911911550306
- FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
- MatsumotoTClaesson-WelshLVEGF receptor signal transductionSci STKE20012001112RE2111741095
- BenjaminLEGolijaninDItinAPodeDKeshetESelective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJ Clin Invest199910321591659916127
- KuDDZaleskiJKLiuSBrockTAVascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteriesAm J Physiol19932652 Pt 2H586H5928368362
- ClaussMGerlachMGerlachHVascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migrationJ Exp Med19901726153515452258694
- GabrilovichDIChenHLGirgisKRProduction of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNat Med1996210109611038837607
- CarmelietPBlood vessels and nerves: common signals, pathways and diseasesNat Rev Genet20034971072012951572
- CalabreseCPoppletonHKocakMA perivascular niche for brain tumor stem cellsCancer Cell2007111698217222791
- RubensteinJLKimJOzawaTAnti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionNeoplasia20002430631411005565
- KunkelPUlbrichtUBohlenPInhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2Cancer Res200161186624662811559524
- PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res19975720459345999377574
- LinYSNguyenCMendozaJLPreclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorJ Pharmacol Exp Ther199928813713789862791
- IgnoffoRJOverview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factorAm J Health Syst Pharm20046121 Suppl 5S21S2615552623
- CabebeEWakeleeHRole of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitorsCurr Treat Options Oncol200781152717634832
- EscudierBCosaertJPisaPBevacizumab: direct anti-VEGF therapy in renal cell carcinomaExpert Rev Anticancer Ther20088101545155718925847
- GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
- HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
- KabbinavarFFHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol200523163706371215867200
- MillerKDE2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancerClin Breast Cancer20033642142212636887
- AliSAMcHaylehWMAhmadABevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 casesJ Neurosurg2008109226827218671639
- NarayanaAKellyPGolfinosJAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalJ Neurosurg2009110117318018834263
- PoulsenHSGrunnetKSorensenMBevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursActa Oncol2009481525819031176
- ZunigaRMTorcuatorRJainREfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493
- KangTYJinTElinzanoHPeereboomDIrinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safetyJ Neurooncol200889111311818438609
- NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600
- NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology200834701077978718316689
- VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
- BallmanKVBucknerJCBrownPDThe relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro Oncol200791293817108063
- LambornKRYungWKChangSMProgression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasNeuro Oncol2008410216217018356283
- FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
- KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
- BatchelorTTGilbertMRSupkoJGPhase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Neuro Oncol200461212714769136
- PradosMDLambornKYungWKA phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyNeuro Oncol20068218919316533878
- MohileNAALLymberisSCKarimiSHouBLGutinPHA pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomasASCO Meeting Abstracts20072518 Suppl2028
- NicholasMKLRArzbaecherJPaleologosNKrouwerHMalkinMBevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II studyASCO Meeting Abstracts20092715S2016
- LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
- NarayanaAGolfinosJGFischerIFeasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade gliomaInt J Radiat Oncol Biol Phys200872238338918793954
- GruberMLRazaSBevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicityASCO Meeting Abstracts20092715S2017
- GilbertMarc R RTOG. Temozolomide and Radiation Therapy with or without Bevacizumab in treating patients with newly diagnosed glioblstoma or Gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00884741
- Hoffmann-LaRocheCTA study of Avastin in combination with Temozolomide and Radiotherapy in patients with newly diagnsoed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826
- AnanthnarayanSBahngJRoringJTime course of imaging changes of GBM during extended bevacizumab treatmentJ Neurooncol2008788333934718389177
- WefelJSCTZazzaliJFriedmanHSfor the BINeurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN studyASCO Meeting Abstracts20092715S20256
- PopeWBKimHJHuoJRecurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentRadiology2009252118218919561256
- DesjardinsABDHerndonJEIIReardonDAQuinnJARichJNDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11)ASCO Meeting Abstracts20072518 Suppl2029
- PaldinoMDAFriedmanHSVredenburghJJBarboriakDPPrognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumabASCO Meeting Abstracts20092715S2058
- Lucio-EterovicAKPiaoYde GrootJFMediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyClin Cancer Res200915144589459919567589
- IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology200973151200120619822869
- QuantECNordenADDrappatzJRole of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumabNeuro Oncol200911555055519332770
- PotthastLCSPanEYuDZhuWBremSThe infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumabASCO Meeting Abstracts20092715S2057